EBF PRESENTATION: Join George today at 09:40 (CET)> TRACK: Smaller, Lower, Higher, Faster, More, Less….Just Better 09:40 - 10:00 George Walters, Exploring the Benefits and Challenges of Universal Automated Methods. #ebf #BioanalyticalSolutions #Bioanalysis

EBF PRESENTATION: Join Szabolcs today at 16:40 (CET)> TRACK: Protein MS 16:40 - 17:00 Szabolcs Szarka, Design of Experiment – a Powerful Tool to Optimise Sample Preparation in Bottom-up Targeted Protein LC-MS Workflows #ebf #BioanalyticalSolutions #Bioanalysis #EBF2022

EBF PRESENTATION: Join Laura today at 17:20 (CET)> TRACK: Immunogenicity Technology - Interference Focus 17:20 - 17:40 Laura Geary, Pushing the Limits of Immunogenicity Assay Drug Tolerance #ebf #BioanalyticalSolutions #Bioanalysis #EBF2022

EBF PRESENTATION: Join Claire today at 09:40 (CET)> TRACK: "Beyond BA" 09:00 - 09:20 Claire Szuster, Plasma Protein Binding: On RED alert! #ebf #BioanalyticalSolutions #Bioanalysis #EBF2022

What a week at #EBF! Everyone really enjoyed meeting up with the bioanalytical community and well done to the whole team at the show and our presenters. #ebf #BioanalyticalSolutions #Bioanalysis

We thoroughly enjoyed our time at BOS Manchester last week. Thank you to those who popped by our stand, we hope you had an enjoyable and insightful time too. #BOSMCR2022 #AnalyticalScience #AnalyticalSolutions #MaterialsScience #PharmaAnalysis #DrugDevelopment

Join Mike Ludlow, Science Lead at the 3rd Annual Extractables & Leachables Conference, where he will be presenting on Experimental Design Considerations. 📆 December 1-2 📍 Berlin, Germany and Virtual ✔ Learn more: buff.ly/3OvDYDk #leachables #extractables

Missed one of our presentations at EBF? With six presentations at EBF this year (the highest by any CRO...) it was easy to miss a session. 📰 Download all six presentations here: buff.ly/3F2FgkO #BioanalyticalSolutions #Bioanalysis #ebf

Our Analytical and Materials Science (AMS) Sandwich Team recently celebrated their 10th Anniversary in an event marking Discovery Park’s 10th Anniversary. AMS Sandwich was founded in 2012 at Discovery Park. Read more > buff.ly/3HbLRvL

LC-MS/MS assay development within bioanalysis is driven by developing accurate, precise & robust methods in the shortest time frame. Discover a generic protocol that enabled us to develop a consistent & efficient process to reach these goals 📰 Download > buff.ly/3gYLVEv

Mike Ludlow, Science Lead for our analytical and materials science division presented at Vonlanthens 3rd Extractables & Leachables conference. 📰 Download the slides here: buff.ly/3XZhPBC

Merry Christmas and a Happy New Year from everyone at Drug Development Solutions. Keep the kids (and any bored adults) busy with our free seasonal activities. 📰 Download buff.ly/3XRydUJ

New Year…New Job? Maybe we can help. Due to our continued success and growth, we have several vacancies available for people with biotech expertise like you. buff.ly/3sNOmw7 #jobs #vacancies #jobsinscience

Upcoming webinar 🖥 Challenges of developing ADA and concentration (PK or PD) assays for lysosomal transgene enzymes on an automated immunoassay platform 📆 January 26, 2023 (08:00 PST; 11:00 EST; 16:00 GMT; 17:00 CET) 📍 Online ✔ Learn more and register: buff.ly/3vA2vOD

Advances in solid form science and regulatory opinion allow a wider range of forms to be considered viable. Our Solid Form Screening and Selection Centre of Excellence supports clients in identifying optimal solid forms for development. ✔ Learn more: buff.ly/3X39trb

Supporting your DDI studies We have built a portfolio of in-house quantitative LC-MS/MS assays, with an emphasis on the probe drugs and inducers/inhibitors recommended in guidance issued by the EMA and FDA. ✔ Learn more: buff.ly/3GcqaK5

Upcoming webinar 🖥 Challenges of developing ADA and concentration (PK or PD) assays for lysosomal transgene enzymes on an automated immunoassay platform 📆 January 26, 2023 (08:00 PST; 11:00 EST; 16:00 GMT; 17:00 CET) 📍 Online ✔ Learn more and register: buff.ly/3vA2vOD

Following the recent requirements regarding risk assessments of marketed products, a significant amount of small molecule related APIs, possibly 30%+, have been shown to have the potential to form active related nitrosamines. Read the blog > buff.ly/3GF909w

For the latest news and updates, visit our LinkedIn profile linkedin.com/company/drugde…